Advertisement
ELOX vs EOCN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELOX is a Buy and EOCN is a Buy.
ELOX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 09, 2026
ELOX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 36 cases where ELOX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ELOX's RSI Oscillator exited the oversold zone, 30 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 63 cases where ELOX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ELOX as a result. In 67 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for ELOX just turned positive on October 27, 2026. Looking at past instances where ELOX's MACD turned positive, the stock continued to rise in 28 of 37 cases over the following month. The odds of a continued upward trend are 76%.
Following a +4.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELOX advanced for three days, in 114 of 130 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
Bearish Trend Analysis
ELOX moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ELOX crossed bearishly below the 50-day moving average on September 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELOX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ELOX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ELOX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.988) is normal, around the industry mean (2.974). P/E Ratio (3.790) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELOX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
EOCN's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for EOCN moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 49 similar instances when the indicator left oversold territory. In 45 of the 49 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where EOCN advanced for three days, in 182 of 213 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
EOCN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EOCN as a result. In 92 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 50-day moving average for EOCN moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EOCN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EOCN entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.319) is normal, around the industry mean (2.974). P/E Ratio (-0.887) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. EOCN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EOCN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ELOX | EOCN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 3 | 95 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 73 Overvalued | 62 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 98 | |
PRICE GROWTH RATING 1..100 | 34 | 83 | |
P/E GROWTH RATING 1..100 | 24 | 19 | |
SEASONALITY SCORE 1..100 | 34 | 34 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EOCN's Valuation (62) in the Pharmaceuticals Other industry is in the same range as ELOX (73) in the Biotechnology industry. This means that EOCN’s stock grew similarly to ELOX’s over the last 12 months.
EOCN's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ELOX (100) in the Biotechnology industry. This means that EOCN’s stock grew similarly to ELOX’s over the last 12 months.
ELOX's SMR Rating (96) in the Biotechnology industry is in the same range as EOCN (98) in the Pharmaceuticals Other industry. This means that ELOX’s stock grew similarly to EOCN’s over the last 12 months.
ELOX's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for EOCN (83) in the Pharmaceuticals Other industry. This means that ELOX’s stock grew somewhat faster than EOCN’s over the last 12 months.
EOCN's P/E Growth Rating (19) in the Pharmaceuticals Other industry is in the same range as ELOX (24) in the Biotechnology industry. This means that EOCN’s stock grew similarly to ELOX’s over the last 12 months.
| ELOX | EOCN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 74% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 76% | N/A |
| TrendWeek ODDS (%) | 1 day ago 68% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 81% | 1 day ago 90% |
| Advances ODDS (%) | 1 day ago 88% | 5 days ago 85% |
| Declines ODDS (%) | 5 days ago 90% | 9 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 89% | 1 day ago 87% |
| Aroon ODDS (%) | 1 day ago 79% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ELOX’s FA Score shows that 1 FA rating(s) are green while EOCN’s FA Score has 1 green FA rating(s).
- ELOX’s FA Score: 1 green, 4 red.
- EOCN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ELOX’s TA Score shows that 6 TA indicator(s) are bullish while EOCN’s TA Score has 3 bullish TA indicator(s).
- ELOX’s TA Score: 6 bullish, 4 bearish.
- EOCN’s TA Score: 3 bullish, 5 bearish.
Price Growth
ELOX (@Biotechnology) experienced а +0.91% price change this week, while EOCN (@Biotechnology) price change was -0.65% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.36%. For the same industry, the average monthly price growth was -13.16%, and the average quarterly price growth was -14.28%.
Reported Earning Dates
ELOX is expected to report earnings on Nov 10, 2026.
EOCN is expected to report earnings on Nov 25, 2026.
Industries' Descriptions
@Biotechnology (-1.36% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ELOX and
Correlation & Price change
A.I.dvisor indicates that over the last year, ELOX has been loosely correlated with XBIO. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ELOX jumps, then XBIO could also see price increases.
| Ticker / NAME | Correlation To ELOX | 1D Price Change % | ||
|---|---|---|---|---|
| ELOX | 100% | +1.29% | ||
| XBIO - ELOX | 59% Loosely correlated | +3.47% | ||
| EOCN - ELOX | 57% Loosely correlated | N/A | ||
| IMMP - ELOX | 47% Loosely correlated | +1.61% | ||
| ENVB - ELOX | 40% Loosely correlated | +2.90% | ||
| SRPT - ELOX | 36% Loosely correlated | +5.06% | ||
More | ||||
EOCN and
Correlation & Price change
A.I.dvisor indicates that over the last year, EOCN has been closely correlated with XBIO. These tickers have moved in lockstep 88% of the time. This A.I.-generated data suggests there is a high statistical probability that if EOCN jumps, then XBIO could also see price increases.
| Ticker / NAME | Correlation To EOCN | 1D Price Change % | ||
|---|---|---|---|---|
| EOCN | 100% | N/A | ||
| XBIO - EOCN | 88% Closely correlated | +3.47% | ||
| ELOX - EOCN | 57% Loosely correlated | +1.29% | ||
| OVID - EOCN | 31% Poorly correlated | +4.87% | ||
| CMMB - EOCN | 30% Poorly correlated | +2.00% | ||
| NVAX - EOCN | 29% Poorly correlated | +6.60% | ||
More | ||||